Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phospholipidated recombinant human copper zinc superoxide dismutase
- Development stage
- Unknown
- Lead developer
- Beijing Tide Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Phospholipidated recombinant human copper zinc superoxide dismutase (L-SOD) is a modified antioxidant enzyme therapy developed by Beijing Tide Pharmaceutical. It consists of recombinant human Cu/Zn superoxide dismutase (SOD1) associated with phospholipids to enhance its stability and prolong its half-life in the systemic circulation. The drug is primarily investigated for its ability to reduce myocardial reperfusion injury in patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). By catalyzing the dismutation of superoxide radicals into oxygen and hydrogen peroxide, it scavenges reactive oxygen species (ROS) that are generated in excess during the restoration of blood flow to ischemic cardiac tissue, thereby mitigating oxidative damage and improving clinical outcomes.
- Other names
- phospholipidated rhCu/Zn SODliposomal recombinant human superoxide dismutaseliposomal SODsudismase
Beyond the preview
Go deeper on phospholipidated recombinant human copper zinc superoxide dismutase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phospholipidated recombinant human copper zinc superoxide dismutase.